[Bilateral uveitis associated with nivolumab therapy]

Abstract

Immune-related adverse events (IRAEs) are rare but serious adverse events that may be associated with inhibitors of few immune control points. The purpose here is to report the case of an inflammatory ocular disease, potentially linked to the immunity and use of nivolumab, a new immunological agent used for the treatment of a solid tumor. In spite of the involvement of this treatment in the onset of inflammation, we must always seek another cause. It is possible to continue this treatment by considering the benefit/risk balance for each patient. Close collaboration between oncologists and ophthalmologists is necessary in the diagnosis and rapid management of these IRAE ocular related to these new emerging therapies.

Keywords: Anti-PD1; Check point inhibitors; Chemotherapy; Chirurgie de la cataracte; Drug induced uveitis; Dysfonctionnement meibomien; Expressibilité meibomienne; Meibographie; Nivolumab; Posterior uveitis; Sécheresse oculaire; Uveitis.